Atrial Cardiomyopathy in Patients With Stroke of Undetected Mechanism

Stroke Clinical Trial

Official title:

Atrial Cardiomyopathy in Patients With Stroke of Undetected Mechanism

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03830983
• Other study ID #: 18055313
• Status: Completed
• Start date: March 8, 2019
• Est. completion date: January 31, 2023

Study information

• Verified date: March 2023
• Source: University Hospital Bispebjerg and Frederiksberg
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The goal of this study is to evaluate left atrial structural and functional abnormalities in stroke of undetected mechanism and atherosclerotic stroke with cardiac MRI.

Description:

Aims and objectives:

The goal of this study is to evaluate left atrial structural and functional abnormalities in patients with stroke of likely cardio-embolic origin compared with healthy age and sex matches controls and patients with atherosclerotic stroke using cardiac MRI.

Background:

Despite standard work up for the etiology of ischemic stroke, about 30% of the cases remain unexplained. It is increasingly accepted that these unexplained cases arise from disease outside of the brain. Paroxysmal AF (Atrial fibrillation) may often be suspected as the source but fewer than one third of patients with stroke of undetermined source manifest AF in any form even after 3 years of continuous heart rhythm monitoring. Emerging evidence suggest that atrial functional and structural abnormalities may convey a comparable risk of stroke in which AF is only one of several features. These abnormalities have been termed "atrial cardiomyopathy" and may be an efficient and practical approach to identify patients at high risk of AF and ischemic stroke.

Methods and materials:

Cross sectional and prospective cohort study with 3 different groups: 50 patients with stroke of undetected mechanism, 50 patients with atherosclerotic stroke (large or small vessel disease) admitted to the University Hospital of Bispebjerg and Frederiksberg and 50 sex and age matched controls with no history of stroke or AF from the Copenhagen City Heart Study (ØBUS) will be included during a 2 year-period. The study will measure atrial structural abnormalities using cardiac magnetic resonance imaging (MRI) and atrial functional abnormalities by cardiac MRI and echocardiography. A 1 year follow up will examine the incidence of silent brain infarction with MRI and incidence of stroke, atrial fibrillation, acute myocardial infarction and cardiovascular death. Secondary endpoints are to examine the association of functional and structural changes found by MRI with echocardiography, rhythm abnormalities and biomarkers with the purpose of finding clinical easily applicable methods to diagnose atrial cardiomyopathy.

Expected outcome and perspectives:

The investigators hypothesize that patients with stroke of likely cardio-embolic origin have significantly more atrial fibrotic degeneration and reduced atrial emptying function than patients with atherosclerotic stroke and the control subjects. The investigators expect a higher incidence of silent brain infarction in the group with stroke of likely cardio-embolic origin. With atrial cardiomyopathy investigated thoroughly in patients with stroke of likely cardio-embolic origin the future work-up and treatment strategies could be more efficient and may thus improve the prognosis in terms of mortality and disability for a considerable number of patients.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 150
• Est. completion date: January 31, 2023
• Est. primary completion date: September 6, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria (Patients):

1. Stroke of likely cardioembolic cause or of undetected mechanism:

Lesions in at least one territory on MRI & absence of significant large vessel disease defined as stenosis of cerebral or pre-cerebral vessels >50% in arteries supplying the ischemic area(s) & absence of severe small vessel disease including micro-bleeds on MRI.

Patients with central retinal artery occlusion documented by perimeter and absence of significant large vessel disease defined as stenosis of cerebral or pre-cerebral vessels >50% & absence of severe small vessel disease including micro-bleeds on MRI are included independent of acute MRI findings.

2. Large or small vessel stroke (atherosclerotic stroke):

Large vessel stroke: Acute lesions in one vascular territory on MRI, significant large vessel disease defined as stenosis of cerebral or pre-cerebral vessels >50% leading to the infarcted territory & absence of severe small vessel disease including micro-bleeds on MRI Small Vessel stroke: MRI documenting lacunar infarction, absence of significant large vessel disease defined as stenosis of cerebral or pre-cerebral vessels >50% and presence of severe small vessel disease possibly including micro bleeds.

3. Ischemic stroke within 30 days prior to inclusion

4. Age > 18 years

5. Life expectancy of at least one year

6. Informed consent

• Stenosis: % defined by Ultrasound

• Small vessel disease: defined according to STRIVE criteria

Inclusion Criteria (Controls)

1. Age and sex matched healthy controls. Matched with the group with stroke of likely cardioembolic stroke.

Exclusion Criteria (Patients):

1. Prior AF or AF >30 sec on at least 6 hours of monitoring during hospitalization.

2. Other major cardio-embolic risk sources assumed as cause of stroke (e.g. endocarditis, myocardial infarction within last 4 weeks, prosthetic cardiac valve)

3. Contraindications to MRI (Including eGFR<30 or other contraindications for the contrast agent used during Cardiac MRI)

4. Assumed unable to participate in the study by investigator (including but not restricted to psychiatric condition, dementia)

Exclusion Criteria (Controls):

1. History of stroke or AF

2. Contraindications to MRI (Including eGFR<30 mL/min/1.73 m2 or other contraindications for the contrast agent used during Cardiac MRI)

3. Assumed unable to participate in the study by the investigator (For the same reasons listed above)

Related Conditions & MeSH terms

• Cardiomyopathies
• Stroke

Locations

Country	Name	City	State
Denmark	Bispebjerg Hospital	Copenhagen NV	Copenhagen

Sponsors (3)

Lead Sponsor	Collaborator
University Hospital Bispebjerg and Frederiksberg	Lundbeck Foundation, Rigshospitalet, Denmark

Country where clinical trial is conducted

Denmark, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Observational study: Assessing incidence of stroke, acute myocardial infarction, atrial fibrillation and cardiovascular-death	Follow up in patient records	1 year from last included patient
Primary	Extent of the fibrosis in the Left Atrium (LA)	Measured with gadolinium enhanced cardiac MRI	Within 12 weeks from index event
Primary	Left Atrial Emptying Function (LAEF)	Measured with gadolinium enhanced cardiac MRI	Within 12 weeks from index event
Secondary	Observational study: Incidence of silent brain infarctions	Incidence of silent brain infarctions assessed by follow-up MR-cerebrum (Only in patients)	Between 1-2 years from index event
Secondary	Left atrial volume	Assessed by cardiac MRI	Within 12 weeks from index event
Secondary	Left atrial appendage morphology	Assessed by cardiac MRI	Within 8 weeks from index event
Secondary	Left atrium volume	2D and 3D left atrial volume assessed by transthoracic echocardiography	Within 12 weeks from index event
Secondary	Left atrium ejection fraction (LAEF)	Assessed by transthoracic echocardiography	Within 12 weeks from index event
Secondary	Speckle tracking of LA	Assessed by transthoracic echocardiography	Within 12 weeks from index event
Secondary	Atrial rhythm abnormalities: Number of premature atrial contractions (PAC) per hour. Number and length of runs of PAC	Assessed by 48-hours Holter monitoring	Within 4 weeks from index event
Secondary	Heart rate variability (HRV)	Time domain variables (meanNN, SDNN, SDANN, SDNNidx, RMSSD, pNN50)	Within 4 weeks from index event
Secondary	Thrombophilia biomarkers	Assessment of hypercoagulability	Within 12 weeks from index event
Secondary	Cardiac specific biomarkers	Atrial Natriuretic Peptide, pro NT-Brain Natriuretic Peptide, High Sensitive Troponins.	Within 12 weeks from index event
Secondary	Inflammatory biomarkers	High Sensitive CRP, Interleukins: IL1, IL1b, IL6, IL18	Within 12 weeks from index event
Secondary	Fibrosis related markers	Collagen type I and III	Within 12 weeks from index event